Immunomodulation-related treatment and adjustment of
immunosuppressive drugs
The dose, type, and hormone use of immunosuppressants after renal
transplantation did not differ significantly among the three groups
(Table 1 in the Appendix). A comparison of immunomodulatory treatments
between the three groups showed that the use of propyl globulin was
highest in the A+P group, with 41.4% of patients using propyl globulin,
followed by the paxlovid group, and lowest in the azvudine group
(P=0.030). Intravenous hormone use also differed among the three groups
(P=0.001), with the highest use in the A+P group (75.9 %) and the
lowest in the azvudine group (37.1 %). The use of monoclonal antibodies
did not differ significantly among the three groups (P=0.171). With
regard to dose adjustment of immunosuppressive agents, the A+P group had
a higher rate of dose reduction and discontinuation of CNI-based
immunosuppressive agents than the paxlovid and azvudine groups, whereas
there was no significant difference between the three groups regarding
dose reduction and discontinuation of MMF-based immunosuppressive agents
(Table 2).
The absolute values of the change in immunosuppressive concentration
before and after pneumonia treatment were 1.7 (2.5, 4.5) in the azvudine
group, 2.1 (0.7, 3.3) in the paxlovid group, and 2.4 (1.4, 2.1) in the
A+P group, with no statistical difference between the three groups,
according to a non-parametric test(P=0.343).